This blog post has moved to:
Thursday, December 29, 2011
Earlier this month, the University of Massachusetts Medical Center in Worcester released an abstract on an SCD-like study.
Led by Professor Barbara Olendzki, the UMass team changed the diet of 8 Crohn's and 3 ulcerative colitis patients who no longer responded to their medications. These medications included immunomodulators and corticosteroids.
After the dietary intervention, 100% of patients had improved significantly. In addition to feeling better according to disease activity indexes, all of the patients were able to stop at least one medication.
The medical school team conducting the study started with the SCD as a base and added several probiotic and prebiotic foods. In addition, the diet removes trans-fatty acids. UMass has dubbed the adjusted diet Anti-Inflammatory Diet for Inflammatory Bowel Disease, or AID-IBD.
At least two other SCD specific studies are in the works as well as other studies that focus on changing the mix of gut bacteria via diet.
In the near future, these studies combined the current basic research being done on the microbiome should fold IBD dietary treatments into the mainstream.
Interestingly, practitioners and researchers in the 1940s, 50s, and 60s had the relationship between digestion/bacteria/IBD in their view. With that focus coming back, one 2012 prediction is that this site will be offline by 2014:)
The abstract of the study may be seen below.
Abstracts from the 2011 Advances in Inflammatory Bowel Diseases Crohn’s & Colitis Foundation’s National Clinical & Research Conference December 1–3, 2011 Hollywood, Florida
An anti-inflammatory diet for Inflammatory Bowel Disease; the IBD-AID Barbara Olendzki, Taryn Silverstein, Gioia Persuitte, Katherine Baldwin,
Yunsheng Ma, David Cave
University of Massachusetts Medical School, Worcester, MA, USA
BACKGROUND AND PURPOSE: Inflammatory Bowel Disease (IBD), which includes Crohn’s Disease (CD) and Ulcerative Colitis (UC), are chronic inflammatory gastro- intestinal disorders. Standard IBD treatment typically employs a combination of anti-inflammatories, immunomodulators and biologics; however, the pharmaco- logical approach is not by itself curative. The Anti-Inflammatory Diet for IBD (IBD- AID) is a nutritional regimen that has been derived from The Specific Carbohydrate Diet (SCD). The IBD-AID restricts the intake of complex carbohydrates such as refined sugar, gluten-based grains, and certain starches from the diet. As in the original SCD, these carbohydrates are thought to provide a substrate for pro-inflammatory bacteria. The IBD-AID also places strong emphasis on the ingestion of pre- and probiotics to help restore the balance of the intestinal flora. A third focus of the IBD-AID is the elimination of trans-fatty acids, and a shift away from foods high in saturated fat and omega-6 polyunsaturated fats, with a proportionate encouragement of foods with omega-3 fatty acids.
The objective was to assess the efficacy of the IBD-AID as an adjunct or alternative to standard IBD therapy.
DESCRIPTION OF THE PROJECT: A literature search for recent studies and review articles was undertaken regarding diet and IBD. After IRB approval, medical records of patients with IBD who have used the IBD-AID to help treat their disease were retro- spectively reviewed. Each patient’s response to the diet was reviewed based on an esti- mated Harvey Bradshaw Index (HBI) or Modified Truelove and Witts score (MTLWS).
RESULTS AND CONCLUSIONS: Of 11 patients, 8 had CD, 3 had UC. The average age was 42.2 years old (age range 19-70 years). Before the dietary intervention, 7 patients (64%) had one or more drug treatment failures, meaning they had adverse side effects, the medication had no effect, or the medication had become ineffective. After using the IBD-AID, all (100%) of the patients were able to discontinue at least one of their prior anti-inflammatories, immunomodulators or biologics. Additionally, all (100%) of the patients had symptom reduction including bowel frequency. The mean HBI pre-IBD-AID was 11 (range 1-20) and the mean follow-up score was 1.5 (range 0-3). The mean MTLWS pre- IBD-AID was 7 (range 6-8) and the mean follow-up score was 0. The average decrease in the HBI was 9.5 and the average decrease in the MTLWS was 7.
This case series indicates the potential for the IBD-AID to be used as an adjunct or alternative therapy for the treatment of IBD. Further randomized, prospective trials are needed. Strategies to improve palatability of and compliance with the IBD-AID are also needed.